24 results about "Hydrochlorothiazide" patented technology

The invention provides benazepril hydrochloride and hydrochlorothiazide tablets and a preparation method thereof, and relates to the technical field of pharmaceutical preparations. The benazepril hydrochloride and hydrochlorothiazide tablet is prepared from the following raw material components: benazepril hydrochloride, hydrochlorothiazide, lactose, hydroxypropyl methylcellulose, polyvinylpolypyrrolidone, hydrogenated castor oil and opadry coating powder. The weight content of the lactose in the benazepril hydrochloride and hydrochlorothiazide tablet is 50 wt%-82 wt%. In the coating process of preparing the tablets, the drying temperature is 30-60 DEG C. The prepared benazepril hydrochloride and hydrochlorothiazide tablet compound preparation is high in stability, high in release rate and low in impurity content. According to the benazepril hydrochloride hydrochlorothiazide tablet, the stability of the product is improved, and the problem that the impurity content of the benazepril hydrochloride hydrochlorothiazide tablet is easy to greatly increase during long-term storage is solved.

The invention provides a pharmaceutical composition. The pharmaceutical composition is prepared from aspirin, atorvastatin, valsartan, hydrochlorothiazide, folic acid substances and pharmaceutically acceptable auxiliary materials. The pharmaceutical composition provided by the invention has the advantages that the pharmaceutical composition provided by the invention has a multi-target synergistic prevention effect on vascular diseases, especially cerebral embolism, that is, the composition not only can reduce blood pressure, blood fat and blood homocysteine level, but also has an effect of preventing thrombosis, and reduces the risk of cerebral apoplexy. In addition, the form of the pharmaceutical composition is beneficial to improving the medication compliance of patients.

The invention relates to the technical field of medicines, and particularly discloses sacubitril / valsartan sodium hydrochlorothiazide tablets and a preparation method of the sacubitril / valsartan sodium hydrochlorothiazide tablets. According to the application, the prescription dosage range of sacubitril valsartan sodium and hydrochlorothiazide is limited. Under the preferable proportion, the dissolution and disintegration characteristics of sacubitril sodium and hydrochlorothiazide can be balanced, the interference between the sacubitril sodium and hydrochlorothiazide is less, the whole sacubitril sodium and hydrochlorothiazide can be disintegrated and released at a relatively high speed, the sacubitril sodium and hydrochlorothiazide can be completely disintegrated within 5 minutes, the dissolution rate of 75% or above can be realized within 60 minutes, and the preparation method is simple and convenient. The traditional Chinese medicine has a good treatment effect on hypertension.

The invention discloses an olmesartan medoxomil pharmaceutical co-crystal as well as a preparation, a preparation method and application thereof. The co-crystal is formed by olmesartan medoxomil and a specific co-crystal forming agent through intermolecular force. The invention also particularly provides a compound preparation containing the olmesartan medoxomil pharmaceutical co-crystal and hydrochlorothiazide. Through the eutectic technology, the invention fundamentally overcomes the inherent defects of low solubility and slow dissolution of olmesartan medoxomil as a BCS II drug. Experiments show that the preparation disclosed by the invention can realize rapid and complete drug release in vitro (the dissolution rate within 30 minutes is greater than or equal to 98%), the relative bioavailability of olmesartan in vivo can be improved by at least 180% compared with that of a reference preparation, and meanwhile, the eutectic structure ensures that the preparation has excellent chemical stability under an accelerated test condition. The invention provides an innovative solution for the development of an efficient and stable olmesartan medoxomil preparation.

The invention relates to the field of pharmaceutical preparations, in particular to a stable lisinopril compound tablet and a preparation method thereof. The compound tablet is prepared from the following components in parts by weight: 10 parts of lisinopril, 12.5 parts of hydrochlorothiazide, 45 to 75 parts of calcium phosphate, 15 to 30 parts of mannitol and 15.5 to 27.5 parts of other pharmaceutically acceptable auxiliary materials. The compound tablet provided by the invention greatly improves the drug stability, greatly facilitates clinical use, improves the quality of a preparation product, and is beneficial to industrial mass production.

The invention relates to the technical field of particle raw material stirring and mixing, in particular to a compound dibazol hydrochlorothiazide capsule raw material pretreatment stirring and mixing device which comprises a plurality of treatment frames which are evenly distributed from top to bottom and provided with upward openings, discharging openings are formed in the bottoms of the treatment frames, and stirring mechanisms are installed in the treatment frames; the device adopts a manner of matching layered laying and alternate stacking, active ingredients are independently stirred and flattened, then the active ingredients and auxiliary materials are stacked layer by layer, the active ingredients are uniformly attached to the surfaces of the auxiliary materials through throwing, and multi-stage gradual dilution is carried out, so that the problem that the active ingredients are easy to disperse and non-uniform when being directly mixed can be solved, the medicine content accuracy is improved, and the medicine quality is improved. And the components of each capsule are uniform and reach the standard.

The invention discloses a preparation method of a hydrochlorothiazide intermediate, which comprises the following steps: reacting 4-amino-6-chloro-1, 3-benzene disulfonyl chloride with ammonia water in tetrahydrofuran to obtain a crude product of 4-amino-6-chloro-1, 3-benzene disulfonamide, heating the crude product in a potassium hydroxide solution, decolorizing and purifying, cooling to 5-10 DEG C, crystallizing, filtering, and drying to obtain the hydrochlorothiazide intermediate. The purity of the hydrochlorothiazide intermediate 4-amino-6-chloro-1, 3-benzene disulfonamide refined product reaches 99.5% or above, the content of a single impurity is controlled to be 0.1% or below, and the process is simple and controllable, easy to reproduce and suitable for industrial production.

The invention discloses a telmisartan and hydrochlorothiazide compound tablet which is characterized in that the telmisartan and hydrochlorothiazide compound tablet comprises a double-layer tablet A and a double-layer tablet B, and the layer A is prepared from telmisartan lipidosome, a diluent and a lubricant; and the layer B is prepared from hydrochlorothiazide, a diluent, a disintegrating agent, a lubricant and an antioxidant. The telmisartan liposome comprises lipid and telmisartan, the dosage ratio of the lipid to the telmisartan is (0.5-2.3): 1, the lipid comprises phospholipid and cholesterol, and in the lipid, the content of the cholesterol accounts for 20%-60% of the total amount of the lipid. The telmisartan liposome comprises lipid, telmisartan and a PH buffer solution, and the PH of the PH buffer solution is 5-7. According to the telmisartan and hydrochlorothiazide compound tablet prepared by the invention, the telmisartan dissolution is good, and the tablet is safe and stable.

The present application relates to the technical field of hyperuricemia modeling, and particularly relates to a method for inducing and constructing a cynomolgus monkey hyperuricemia model and application thereof, comprising the following steps: S1: selecting male cynomolgus monkeys as model animals; S2: administering an inducing agent to the experimental animals, wherein the inducing agent is composed of hydrochlorothiazide, potassium oxonate and adenine. The inducing agent is added to ordinary monkey feed for normal feeding of the experimental animals, the intake dose of hydrochlorothiazide is 0.1 g / kg / day, the intake dose of potassium oxonate is 0.2 g / kg / day, the intake dose of adenine is 0.1 g / kg / day, and 10% fructose water is used to replace ordinary drinking water at the same time. The present application can induce a stable hyperuricemia state in the cynomolgus monkey body by means of dietary induction, combined use of hydrochlorothiazide, potassium oxonate and adenine, compared with a traditional model induced by a single intraperitoneal injection of a drug, the present application better simulates the pathogenic cause of human hyperuricemia, and is easier to operate.

The application discloses irbesartan and hydrochlorothiazide tablets and a preparation method thereof. The tablet comprises irbesartan granules and hydrochlorothiazide granules. The irbesartan granules comprise irbesartan, hydroxyphenyl cellulose, glycerophosphoric acid calcium, a disintegrant and a binder. The hydrochlorothiazide granules comprise hydrochlorothiazide, a diluent, a disintegrant and a binder. The tablet can solve the problems of easy agglomeration of irbesartan and hydrochlorothiazide, and difficulty in controlling the content uniformity due to the great difference in the dosage. Meanwhile, the tablet can effectively overcome the poor solubility of irbesartan and hydrochlorothiazide, and good dissolution effect is obtained.

The invention provides a pharmaceutical composition. The pharmaceutical composition is prepared from amlodipine with the minimum hypertension treatment dosage of 20%-50%, valsartan with the minimum hypertension treatment dosage of 20%-50%, metoprolol with the minimum hypertension treatment dosage of 20%-50%, hydrochlorothiazide with the minimum hypertension treatment dosage of 20%-50%, homocysteine reducing medicine and pharmaceutically acceptable auxiliary materials. The pharmaceutical composition is used for treating hypertension, is especially suitable for hypertension with heart failure, and can reduce the death risk of patients.

The invention discloses a three-compound composition of olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide and a preparation method of the three-compound composition. The three-compound preparation comprises three active ingredients of olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide, the auxiliary materials comprise pregelatinized starch, silicified microcrystalline cellulose, cross-linked carboxymethyl cellulose, polylactic acid spray-dried powder, tocopherol and the like; an olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet obtained after coating operation of the olmesartan medoxomil, amlodipine and hydrochlorothiazide three-compound composition is stable in dissolution, consistent with an original product, very smooth in surface, free of dents and more stable in quality.

The invention discloses a method for detecting related substances of telmisartan and hydrochlorothiazide double-layer tablets. According to the detection method disclosed by the invention, octyl silane bonded silica gel is used as a filling agent or a chromatographic column with equivalent efficiency, and an impurity trapping column is added; carrying out gradient elution by taking an ammonium dihydrogen phosphate solution as a mobile phase A and acetonitrile-methanol in a volume ratio of 1: 1 as a mobile phase B; dual wavelength detection is adopted, and the detection wavelengths are 268 nm to 272 nm and 296 nm to 300 nm. The detection method provided by the invention can realize effective separation and quantitative calculation of related substances of two active components (telmisartan and hydrochlorothiazide) in a telmisartan bulk drug, a hydrochlorothiazide bulk drug and a telmisartan and hydrochlorothiazide double-layer tablet, and has the characteristics of good sensitivity, specificity, accuracy, durability and the like; and meanwhile, the working efficiency is greatly simplified.

The invention discloses a method for determining the content of formaldehyde in a hydrochlorothiazide bulk drug, which comprises the following steps: precisely weighing a formaldehyde solution, adding acetonitrile, an acetonitrile solution of 2, 4-dinitrophenylhydrazine and a phosphoric acid solution, and diluting to prepare a reference substance solution; the method comprises the following steps: precisely weighing a hydrochlorothiazide bulk drug, adding acetonitrile, an acetonitrile solution of 2, 4-dinitrophenylhydrazine and a phosphoric acid solution, and diluting to prepare a test solution; the method comprises the following steps: precisely measuring an acetonitrile solution of 2, 4-dinitrophenylhydrazine, a phosphoric acid solution and 1ml of acetonitrile, and diluting with acetonitrile to prepare a blank solution; analyzing by adopting high performance liquid chromatography, precisely measuring the blank solution, the test solution and the reference substance solution, respectively injecting into a liquid chromatograph, recording chromatograms, and calculating by peak area according to an external standard method to obtain the content of formaldehyde in the hydrochlorothiazide bulk drug. The method has the remarkable effects that the method has the characteristics of simple process, low use cost, good precision, high accuracy and the like, and the content of formaldehyde in the hydrochlorothiazide bulk drug can be rapidly measured.

The invention provides a losartan potassium and hydrochlorothiazide pharmaceutical composition and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations, the composition is a tablet, and comprises the following components by weight: 15%-25% of losartan potassium, 5%-10% of hydrochlorothiazide, 10%-30% of a hydrophilic polymer carrier, 0.1%-5% of a pH regulator, 40%-60% of a filler, 3%-15% of a disintegrating agent, 0.5%-2% of a lubricant, and 1%-5% of an adhesive. The preparation method is divided into two methods, one method is a dry granulation process, material pretreatment is firstly carried out, and then tabletting is carried out after primary granulation, premixing, secondary granulation and total mixing; and the other method is a direct mixing process, the particle size of the solid dispersion is controlled after the materials are pretreated, and premixing, total mixing and direct tabletting are performed. According to the invention, the bioavailability of hydrochlorothiazide can be effectively improved, the drug can be rapidly dissolved out to take effect, the long-term stability of the preparation is obviously improved, the process reproducibility is good, and the preparation is suitable for industrial production.

The invention belongs to the field of medicaments, and provides candesartan cilexetil, 5-8 mg of hydrochlorothiazide, 7-10 mg of PEG (polyethylene glycol) 8000, 60-90 mg of lactose monohydrate, 3-8 mg of HPMC (hydroxypropyl methyl cellulose), 0.1-1 mg of magnesium stearate and 3-8 mg of disintegrating agent per 110 mg of the candesartan cilexetil, the hydrochlorothiazide, the PEG 8000, the lactose monohydrate, the HPMC, the magnesium stearate and the disintegrating agent. By selecting a proper disintegrating agent combination, the candesthia tablet disclosed by the invention effectively improves the dissolution performance in artificial gastric juice, and a basis is provided for further improvement of the drug effect.

The invention provides an irbesartan solid dispersion and a preparation method of a preparation thereof, and belongs to the technical field of pharmaceutical preparations, the irbesartan solid dispersion is prepared from 10-30% by weight of irbesartan, 60-90% by weight of copovidone and 5-15% by weight of a plasticizer by adopting a twin-screw hot melt extrusion process, and the irbesartan solid dispersion is prepared from the preparation method of the irbesartan solid dispersion and the preparation of the irbesartan solid dispersion. And mixing the solid dispersion with a filling agent, a disintegrating agent and a lubricating agent which are conventional in pharmaceutics to prepare irbesartan unilateral tablets, or additionally adding hydrochlorothiazide and mixing to prepare irbesartan compound tablets. According to the irbesartan tablet and the preparation method thereof, irbesartan is prepared into the solid dispersion and then prepared into the tablet, so that the electrostatic agglomeration of irbesartan is improved to improve the mixing uniformity of the preparation, the dissolution performance of irbesartan is remarkably improved, and the bioavailability of the medicine is improved; therefore, the problems of insufficient subsequent mixing uniformity caused by electrostatic agglomeration in irbesartan preparation preparation and poor dissolution performance and low bioavailability caused by low solubility are effectively solved.

The invention discloses a method for determining hydrochlorothiazide, caffeine, phenolphthalein, fenofibrate, bisacodine and indapamide in a soft capsule, which comprises the following steps: preparing 2 ng / mL, 5 ng / mL, 10 ng / mL, 20 ng / mL, 50 ng / mL and 100 ng / mL mixed standard working curve solutions; separating capsule shells and contents of the soft capsule samples, and fully and uniformly mixing to obtain capsule contents; weighing capsule contents, adding acetonitrile, extracting, centrifuging, taking supernate, diluting with acetonitrile to a constant volume, and uniformly shaking to obtain an extracting solution; transferring the extracting solution into a purifying column, and collecting a purifying solution to prepare a sample solution; and firstly determining the standard working curve solution by using a chromatographic instrument, and then determining the sample solution to obtain a sample concentration value. The method comprises the following steps: uniformly mixing a sample in a vortex manner, carrying out centrifugal treatment, purifying the centrifuged supernatant, and determining; a first sieve plate, a PSA purification layer, a second sieve plate, a silica purification layer, a microporous filter membrane and a third sieve plate are arranged in the adopted purification column, so that a better purification effect is achieved, and the problem of matrix interference is effectively solved.

The invention discloses a candesartan cilexetil and hydrochlorothiazide compound preparation and a preparation method thereof. The preparation method comprises the following steps: preparing a solid dispersion from candesartan cilexetil and a Soluplus (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol grafted copolymer)-TPGS (vitamin E polyethylene glycol succinate) dual-carrier system by adopting a low-temperature hot-melt extrusion technology, mixing the solid dispersion with hydrochlorothiazide granulated by a fluidized bed, and tabletting. The dissolution speed and bioavailability of candesartan cilexetil are improved, and the stability of the product is ensured.

The application discloses an antihypertensive compound preparation, which comprises 4.0% benazepril hydrochloride, 5.0% hydrochlorothiazide, 78-82% diluent, 6-11% disintegrant, 2-3% lubricant and coating material in percentage by weight. The diluent is selected from one or more of lactose and microcrystalline cellulose, the ratio of the amount of lactose to the amount of microcrystalline cellulose is (10-13):(1-2), the disintegrant is crospovidone, the lubricant is hydrogenated castor oil, and the particle size of benazepril hydrochloride and hydrochlorothiazide is D90<70 mu m. The benazepril hydrochloride and hydrochlorothiazide tablet provided by the application has good stability and dissolution performance.

The application discloses a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide and a preparation method thereof. The triple combination preparation comprises three active ingredients of olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide, and further comprises pre-gelatinized starch, silicified microcrystalline cellulose, cross-linked carboxymethyl cellulose, polylactic acid spray-dried powder and tocopherol as auxiliary materials. The triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide is coated to obtain olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide tablets, which have the same dissolution stability as the original research product, a very smooth surface, no indentation and more stable quality.

The invention provides a method for catalytically synthesizing a 3, 4-dihydrobenzothiadiazine medicine by using rare earth. According to the method, trifluoromethanesulfonic acid rare earth salt is taken as a catalyst, 4-amino-6-chlorobenzene-1, 3-disulfonamide, 4-amino-6-trifluoromethylbenzene-1, 3-disulfonamide and corresponding aldehyde are taken as raw materials, and seven 3, 4-difluorobenzene-1, 3-disulfonamide compounds are simply and conveniently prepared through one-step reaction. The compound is prepared from 2, 4-dihydrobenzothiadiazine medicines: cyclothiazide, buthiazide, cyclopenthiazide, hydrochlorothiazide, bendrofluthiazide, penfluthiazide and ethyl thiazide. The medicine has the effects of inducing diuresis, reducing blood pressure, resisting anxiety, resisting depression, treating edema and the like clinically. The synthesis method provided by the invention has the advantages of mild reaction conditions, simple operation, simple steps and high synthesis efficiency, has industrial application prospects, and plays a positive role in the fields of medicines, fine chemical engineering and the like.

The utility model discloses an olmesartan medoxomil and hydrochlorothiazide tablet packaging device, which relates to the technical field of tablet packaging, and comprises a packaging bottle and a sealing cover, a sealing ring is fixedly arranged below the sealing cover, the sealing ring is in threaded connection with an upper opening of the packaging bottle, the upper part of the sealing cover is a collecting cavity, a sliding table is arranged at the top of the collecting cavity, and the sliding table is strip-shaped; a through medicine outlet is formed in the middle of the sliding table, sliding rails are arranged on the sliding table and located on the front side and the rear side of the medicine outlet, a sliding frame is slidably arranged on the sliding rails, a transparent cover is fixedly arranged on the upper surface of the sliding frame, and a concave separation groove is formed in the side edge of the sliding table and located between the sliding rails. The novel olmesartan medoxomil and hydrochlorothiazide tablet bottle is simple in structure, according to the shape and characteristics of olmesartan medoxomil and hydrochlorothiazide tablets, the tablets are packaged through the bottle body, a single tablet can be taken out when the tablets are taken out, the problems that too many tablets are poured out, the bottle cap is frequently opened, and the tablets are affected with damp can be solved, practicability is high, and the novel olmesartan medoxomil and hydrochlorothiazide

This invention discloses a method for purifying hydrochlorothiazide, comprising dissolving crude hydrochlorothiazide in a mixture containing acid and solvent under heating conditions; then neutralizing with alkali under cooling conditions; and finally obtaining purified hydrochlorothiazide by cooling, crystallization, and filtration. The method provided by this invention further improves both the quality and purification yield of the hydrochlorothiazide product.